To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification
Evotec will apply its state-of-the-art Screening Platform and proprietary GPCR modeling software to identify and validate novel modulators against various targets selected by Takeda Cambridge.
Dr Mario Polywka, Chief Operating Officer at Evotec stated: “We are proud to be selected by Takeda Cambridge to collaborate on this important project. We have invested significantly in our world leading, hit-identification platform and this alliance further validates the strength of this platform and Evotec’s ability to bring value to its partner’s drug discovery efforts. We look forward to working with Takeda Cambridge.”
Dr Andrew Ayscough, Director of Chemistry at Takeda Cambridge, commented: “We are pleased to have this opportunity to work with Evotec making use of their hit identification platform.”
No financial details are disclosed.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
